[Federal Register Volume 66, Number 50 (Wednesday, March 14, 2001)]
[Notices]
[Page 14910]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 01-6272]



[[Page 14910]]

-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Government-Owned Inventions; Availability for Licensing

AGENCY: National Institutes of Health, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The inventions listed below are owned by agencies of the U.S. 
Government and are available for licensing in the U.S. in accordance 
with 35 U.S.C. 207 to achieve expeditious commercialization of results 
of federally-funded research and development. Foreign patent 
applications are filed on selected inventions to extend market coverage 
for companies and may also be available for licensing.

ADDRESSES: Licensing information and copies of the U.S. patent 
applications listed below may be obtained by contacting Susan S. 
Rucker, J.D., at the Office of Technology Transfer, National Institutes 
of Health, 6011 Executive Boulevard, Suite 325, Rockville, Maryland 
20852-3804; telephone 301/496-7056 ext. 245; fax 301/402-0220; e-mail 
[email protected]. A signed Confidential Disclosure Agreement will be 
required to receive copies of the patent applications.

Hybrid Adeno-Retroviral Vector for the Transformation of Cells

C Zheng, B O'Connell, BJ Baum (NIDCR)
Serial No. 60/265,198 filed Jan 30, 2001
    This invention described and claimed in this patent application 
provides for novel hybrid vectors which may be used for cell 
transformation either in vivo, in vitro, or ex vivo. The hybrid 
vectors, which are capable of integrating into the chromosome of the 
host cell and are capable of transforming dividing or non-dividing 
cells, have an adenoviral backbone and only a single retroviral long 
terminal repeat (LTR). Due to their hybrid nature, these vectors 
provide a means of efficient, reliable, long-term gene expression. 
Furthermore, unlike other chimeric or hybrid vector systems only a 
single vector is required to deliver a transgene of interest and 
retroviral structural proteins are not required. The vectors may be 
packaged and delivered via a viral particle or directly to the target 
cell.

ARG, a Human Gene Related to but Distinct From ABL Proto-Oncogene

GD Kruh, SA Aaronson (NCI)
Serial No. 07/559,029 filed Jul 30, 1990 now US Patent 5,693,778 issued 
Dec 02, 1997
    This patent relates to the identification, isolation and cloning of 
the gene ARG (abelson related gene) also known as ABL2. ARG/ABL2 is 
located on the long arm of chromosome 1 at 1q24-q25. It is a non-
receptor tyrosine kinase. Recent work, by Iijima, et al. Blood 95(6): 
2126-2131 (March 15, 2000) and Cazzaniga, et al Blood 94(12):4370-4373 
(December 15, 1999), has demonstrated that ABL2/ARG is a partner with 
the ETV6/TEL gene. ETV6/TEL, located on the short arm of chromosome 12 
at 12p13 has previously been implicated in hematological disease, 
particularly leukemias, through chromosomal translocations. The fusion 
protein derived from this partnership between ETV6/TEL and ARG/ABL2 
includes exons 1-5 of ETV6 (5' PNT region) and the 3' portion of ARG/
ABL2 beginning with exon 1B or 2 which contains all of the functional 
domains of ARG/ABL2. This new work suggests that ARG plays a role in 
AML and possibly other leukemias.
    This work has been published at Kruh GD, et al. Science 
234(4783):1545-8 (Dec 19, 1986) and Kruh GD, et al. PNAS, USA 87:5802 
(Aug 1990).

    Dated: March 6, 2001.
Jack Spiegel,
Director, Division of Technology, Development and Transfer, Office of 
Technology Transfer, National Institutes of Health.
[FR Doc. 01-6272 Filed 3-13-01; 8:45 am]
BILLING CODE 4140-01-P